GlassScriptPhysician profile
Hui S Kang
NPI 1255547998
$19,737.74
in general payments reported to CMS, 2019-2025
48 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,097 · 2020: $2,782 · 2021: $3,155 · 2022: $1,809 · 2023: $3,443 · 2024: $3,623 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,058 · Travel and Lodging: $821 · Gift: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,058.31 |
| Travel and Lodging | $820.65 |
| Gift | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,519.75 | 2019-2024 | Spectra Wavewriter, Wavewriter Alpha Prime 16, Infinion 16 |
| Abbott Laboratories | $1,407.56 | 2019-2025 | Proclaim, Eterna |
| Biohaven Pharmaceuticals, INC. | $1,370.79 | 2021 | |
| Nalu Medical, INC. | $1,139.63 | 2022-2025 | Nalu Neurostimulation System |
| Pfizer INC. | $1,133.53 | 2019-2025 | |
| Painteq LLC | $1,104.53 | 2022-2024 | Painteq |
| Collegium Pharmaceutical, INC. | $980.85 | 2019-2025 | Xtampza |
| Genesys Orthopedics Systems, L.L.C. | $795.88 | 2023 | Sacroiliac Joint Fusion System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $765.32 | 2019-2025 | Relistor |
| Abbvie INC. | $527.04 | 2021-2025 | |
| Merz North America, INC. | $455.01 | 2023-2024 | Xeomin |
| Scilex Pharmaceuticals INC. | $439.45 | 2021-2025 | Ztlido |
| Medtronic, INC. | $433.15 | 2021-2025 | Intellis Adaptivestim, V-Loc 180, Inceptiv |
| Eisai INC. | $397.20 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $260.79 | 2023-2025 | Horizant, Horizant |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.